Business Wire

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...
The American Journal of Managed Care

FDA Approves Ranibizumab Implant in Treatment of DME

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
The American Journal of Managed Care

Visual Acuity, Retinal Sensitivity Improved With Intravitreal Ranibizumab Injection

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...
Verywell Health on MSN

New diabetic macular edema treatment cuts monthly eye injections to twice a year

Fact checked by Jennifer Klump Key Takeaways Susvimo is an FDA-approved eye implant for diabetic macular edema that can be refilled every six months instead of requiring monthly injections.Diabetic ...
MedPage Today

Ranibizumab Ocular Implant Shows Long-Term Benefits in Retinal Disease

The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...
Business Wire

FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States

Patients should not use Lucentis if they have an infection in or around the eye or are allergic to Lucentis or any of its ingredients. Lucentis is a prescription medication given by injection into the ...
Nasdaq

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...
News Medical

Risk for endophthalmitis no higher with Avastin, finds study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug ...
Reuters

U.S. FDA staff say Roche drug helped diabetics see

* Treats most common vision loss in people of working age * FDA staff say higher dose linked to more deaths * FDA advisers to review drug on Thursday By Anna Yukhananov WASHINGTON, July 24 (Reuters) - ...
Medscape

Will 2024 Be Easier on the Eyes?

The burdens that monthly or every-other-month injections in the eye impose on patients with retinal diseases are well-known to be barriers to care for many people with these conditions. Making ...
Nasdaq

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...